Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS ANGPTL3-LRx in Healthy Volunteers With Elevated Triglycerides and Participants With Familial Hypercholesterolemia

Inclusion Criteria for All Cohorts: * Must have given written informed consent and be able to comply with all study requirements * Males or females 18 to 65 years, inclusive, at the time of informed consent * Body Mass Index (BMI) ≤ 35.0 kg/m2 * Females must be non-pregnant and non-lactating, and either surgically sterile or postmenopausal. * Males must be surgically sterile, abstinent or using an acceptable contraceptive method Inclusion criteria for Cohorts, A, D, and AA to DD only: * Fasting triglycerides (TG) ≥ 150 mg/dL at Screening * Fasting low density lipoprotein cholesterol (LDL-C) \> 70 mg/dL at Screening Inclusion criteria for Cohorts B and C only: * Fasting TG 90 - 150 mg/dL at Screening * Fasting LDL-C \> 70 mg/dL at Screening Inclusion Criteria for Cohort EE Only: * Homozygous FH diagnosis and fasting LDL-C ≥ 190 mg/dL (4.9 mmol/L) Inclusion Criteria for Cohort FF Only: * Heterozygous FH diagnosis and fasting LDL-C ≥ 160 mg/dL (4.1 mmol/L) Inclusion Criteria for Cohorts EE and FF Only: * Maximally tolerated stable LDL-C lowering agents (stable for at least 12 weeks) * On stable low-fat diet * Stable weight (± 4 kg) for ≥ 6 weeks prior to screening Exclusion Criteria for All Cohorts: * Known history or positive test for Human Immunodeficiency Virus (HIV), Hepatitis C (HCV), or Hepatitis B (HBV) * Treatment with another Study Drug, biological agent, or device within one-month or 5-half-lives of screening * Regular use of alcohol within 6 months of scr…